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The frequency of dermatological manifestations in diseases due to mitochondrial 
DNA mutations is not well known, although multiple symmetric lipomatosis has been 
repeatedly associated to mitochondrial DNA mutations. Here, we present a patient 
suffering from multiple symmetric lipomatosis and other skin signs. We found a new 
mitochondrial DNA mutation, m.8357T>C, in the tRNALys-coding gene and, using a cybrid 
approach, confirmed its pathogenicity. A meta-analysis of the dermatological signs of the 
patient shows that they are not common in patients with confirmed mitochondrial DNA 
mutations and suggests that, in these cases, lipomatosis is not related to the oxidative 
phosphorylation dysfunction, but to an alteration of an additional function associated to 
particular mitochondrial tRNAs.
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Several key components of the oxidative phosphorylation (OXPHOS) system, the 
main biochemical pathway for energy production, are coded in the mitochondrial DNA 
(mtDNA). In OXPHOS disorders due to mtDNA pathological mutations, the most affected 
tissues are usually those with the highest energy requirements. Cultured dermal fibroblasts 
are frequently used for diagnosing mitochondrial diseases due to mtDNA mutations, 
because OXPHOS defects are detectable in these cells 1. However, OXPHOS disorders 
are not normally accompanied by obvious skin manifestations 2.
Here, we describe a patient with multiple symmetric lipomatosis (MSL), a rare 
disease primarily involving adipose tissue and characterized by the presence of not 
encapsulated fat masses, symmetrically disposed at characteristic body sites (neck, trunk, 
proximal parts of upper and lower limbs). The patient also showed other skin signs. We 
found a novel mutation in his mtDNA and confirmed its pathogenicity. Then, we review the 
literature on dermatologic manifestations in patients with confirmed mtDNA pathological 
mutations.
MATERIALS AND METHODS
DNA extraction, mtDNA sequencing, nuclear DNA (nDNA) genetic fingerprint, 
cybrids construction and analyses were performed as previously reported 3,4. 
RESULTS
Case report
We described previously the case of a 37-year-old male suffering from MSL (Figure 
1A, B) 5. At the age of 9-year-old, he presented with erythematous-scaly and pruritic 
plaques on the face, forearms and the palms of both hands. Lesions on the palms were 
repeated at 17 and 37-year-old. The skin was dry with hyperkeratosis on both hands with 
predominance of palms. Now, at the age of 47-year-old, desquamative lesions in right 
thumb and index are appreciated (Figure 1C). The patient (III-1 in Figure 1D) also showed 
brachycephaly and facial asymmetry, degenerative discopathy, bilateral microlithiasis, 
sporadic elevation of blood pressure, hyperuricemia and mixed dyslipidemia. No 
neurological abnormalities or important developmental problems were reported.
The mother of the proband (II-1 in Figure 1D) presented with lipoma at the 
abdominal level (16 x 12 cm) and in the left shoulder (9 x 7 cm). She also suffered from 
osteoarthritis at the cervical level, a herniated disc at L4-L5 and controlled arterial 
hypertension. A maternal half sister (III-2) presented lipoma type lesions at the abdominal 
level and the maternal half brother (III-3), from a third father, was healthy. Four paternal 
half sibs from two different mothers were also healthy (Figure 1D).
Ethical approval for this study was obtained from involved Institutional Review 
Boards. Written informed consent from the patient was also obtained.
mtDNA analysis
mtDNA sequencing showed an m.8357T>C heteroplasmic transition in the MT-TK 
gene coding for the tRNALys (Figure 2A). The mutation percentage was 53 and 65 % in two 
different blood samples from the patient (III-1 in Figure 1D), and 43 and 38 % in blood 
samples of his mother (II-1) and half maternal sister (III-2), respectively (Figure 2B). This 































































mutation has not been previously found in 49,135 human mtDNA sequences (GenBank, 
accessed October 31st 2019). The change breaks a Watson-Crick base pair in the tRNALys 
acceptor stem (Figure 2C), which is found in 112 out of 114 mammal species 
(http://mamit-tRNA.u-strasbg.fr/). According to MitoTIP 6, an in silico tool for predicting 
pathogenicity of novel mtDNA tRNA variants, m.8357T>C would be possibly pathologic. 
Confirmation of pathogenicity by the use of cybrid cell lines
To confirm the pathogenicity of the mutation, we generated cybrids by fusion of 
osteosarcoma-143B cells with no mtDNA (rho0 cells) and platelets from the patient or 
controls. Since platelets contain mitochondria and mtDNA but not nucleus or nDNA, the 
fusion allows the transfer of the mtDNA to a common nuclear background. The resulting 
cybrid cell lines share their nDNA but differ in their mtDNA. Therefore, phenotypic 
differences among them will be due to the mtDNA that they harbor. We built three different 
cybrids: one with the m.8357T>C mutation (O8357) of the patient; one positive control 
harboring an already confirmed tRNAlys pathological mutation, m.8344A>G (O8344); and 
one negative control with no pathological mutations (Owt). 
First of all, we confirmed that all the three cybrids had the same nDNA. Fifteen out 
of 16 short tandem repeats (STRs) were shared in these cybrids (including 8 out of the 9 
STR markers reported in the American Type Culture Collection for the osteosarcoma-143B 
cell line), thus confirming the nDNA homogeneity. Owt and O8344 cybrids had gained a 
new allele for the CSF1PO marker (12 and 13 versus only 12). We next confirmed the 
mtDNA genetic background in the cybrids (GenBank MN095205, MN095206, and 
MN095207 for Owt, O8344 and O8357, respectively). The O8357 cybrid was homoplasmic 
for the m.8357T>C mutation and the O8344 was heteroplasmic (55 %) for the m.8344A>G 
mutation (Figure 3A). 
The O8357 cybrid showed reduced gro th rate, both in glucose and galactose 
media, when compared with the Owt cybrid (Figure 3B). Moreover, like for the O8344 
cybrid, the endogenous, leak and uncoupled oxygen consumption were significantly lower 
in O8357 cells (Figure 3C). The specific activity and quantity of respiratory complex IV 
(CIV), and p.MT-CO1 subunit levels from CIV were also significantly reduced in both 
cybrids when compared with the control cybrid (Figure 3D-F). 
Literature meta-analysis
A review of the literature searching for the skin manifestations found in our patient, 
allowed us to find 49 index cases, plus 61 maternal relatives, harboring mtDNA 
pathological mutation and suffering from MSL (Supplementary Table): 16.3 % had mtDNA 
deletions; 4.1 % had point mutations in tRNALeu and 79.6 % had point mutations in tRNALys. 
Our patient also showed hands hyperkeratosis mainly in the palms. This sign was 
also found in four pedigrees, harboring the m.7445A>G mutation that affects the 
processing of tRNASer showing hyperkeratosis as a sign of a keratoderma palmoplantar 
and deafness syndrome 7-10. Hyperkeratosis was also described in a patient with MELAS 
syndrome harboring an m.3243A>G mutation in the tRNALeu 11. Regarding the 
erythematous-scaly and pruritic plaques, we only found two previous patients with mtDNA 
pathological mutations and showing these plaques. Both patients harbored the 
m.3243A>G mutation in the tRNALeu 11,12. 
DISCUSSION































































Our results strongly support that the new maternally transmitted m.8357T>C 
transition is the etiologic factor for the MSL of this patient. This is sustained by the fact that 
this change was not previously found in a large collection of mtDNA sequences, it was 
heteroplasmic and broke a conserved Watson-Crick base pair in the base of the tRNALys 
acceptor stem. Moreover, when the patient’s mtDNA was transferred to a rho0 cell line, the 
OXPHOS defect was also transmitted to the cybrids, in a similar way to other already 
confirmed tRNALys pathological mutations 13,14. Finally, lipomas segregated in the pedigree 
along with the mutation.
The frequency of skin abnormalities in mtDNA disorders is not known 15, possibly 
because they are not generally reported in the description of these pathologies 2. 
Interestingly, two associations between mtDNA mutations and skin manifestations have 
been repeatedly described: m.7445A>G mutation and keratoderma palmoplantar; and 
mutations in the MT-TK gene and MSL. However, our meta-analysis and other studies 
suggest that skin anomalies are not frequent in patients with confirmed mtDNA mutations 
16. 
Thus, MSL could not due to the OXPHOS dysfunction originated by a defect in the 
mitochondrial translation, but to the alteration of an additional function associated to these 
particular tRNAs 17. In this sense, it has been suggested that MSL could be the result of a 
disorder of proliferation and differentiation of brown adipose tissue (BAT) cells 18. The 
BAT-specific UCP1 mRNA is expressed in lipomas from MSL patients with the 
m.8344A>G mutation 19. This mutation is associated to increased mitophagy 20 that 
promotes the release of mitochondrial tRNALys molecules. Once in the cytoplasm tRNALys 
interacts with the cytosolic YBX1 protein 21. YBX1 cooperates with EWS protein and both 
activate the transcription of Bmp7 22, a critical early brown adipogenic factor. Since not all 
patients harboring tRNALys mutations develop lipomas, another factor must be also 
involved in the process. 
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FIGURE LEGENDS
Figure 1. Clinical characteristics of the patient. A) Posterior view of the neck and shoulders 
with increased volume due to lipomas. B) Computational tomography of the neck (sagittal 
section) showing a space-occupying lesion hypodense with well-defined edges in relation 
to fat content. C) Desquamative, dirty looking lesion on right thumb. D) Pedigree. III-1 is 
the proband. The mutation percentage in blood (B) is indicated.
Figure 2. m.8357T>C mutation in the mtDNA. A) Electropherogram of a segment of the 
patient’s mtDNA sequence showing the heteroplasmic m.8357T>C transition. B) RFLP gel 
showing the mutation load in blood from the patient (P1 and P2), the mother (M) and the 
half-sister (HS). A, amplicon. C-, negative control. C) Secondary structure of the 
mitochondrial tRNAlys. The mutated position is indicated. 































































Figure 3. Biochemical characterization of the cybrid cell lines. A) RFLP gel confirming the 
presence of the mtDNA pathological mutations m.8344A>G and m.8357T>C in the 
respective cell line. M, molecular weight marker. A, amplicon. B) Growing curves in 
glucose or galactose media. C) Oxygen consumption. E, endogenous respiration; L, 
leaking respiration; and U, uncoupled respiration. White, grey and black bars represent 
Owt, O8344 and O8357 cybrids, respectively. *, p < 0.05 (vs Owt). D) Respiratory complex 
IV (CIV) specific activity (s.a.) normalized by citrate synthase (CS) s.a. E) CIV quantity (q.) 
normalized by CS s.a. F) Western blot showing the amount of the mtDNA-encoded p.MT-
CO1 subunit from CIV. The levels of the nDNA-encoded SDHA subunit from respiratory 
complex II (CII) have been used to normalize. 































































Figure 1. Clinical characteristics of the patient. A) Posterior view of the neck and shoulders with increased 
volume due to lipomas. B) Computational tomography of the neck (sagittal section) showing a space-
occupying lesion hypodense with well-defined edges in relation to fat content. C) Desquamative, dirty 
looking lesion on right thumb. D) Pedigree. III-1 is the proband. The mutation percentage in blood (B) is 
indicated. 































































Figure 2. m.8357T>C mutation in the mtDNA. A) Electropherogram of a segment of the patient’s mtDNA 
sequence showing the heteroplasmic m.8357T>C transition. B) RFLP gel showing the mutation load in blood 
from the patient (P1 and P2), the mother (M) and the half-sister (HS). A, amplicon. C-, negative control. C) 
Secondary structure of the mitochondrial tRNAlys. The mutated position is indicated. 
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Figure 3. Biochemical characterization of the cybrid cell lines. A) RFLP gel confirming the presence of the 
mtDNA pathological mutations m.8344A>G and m.8357T>C in the respective cell line. M, molecular weight 
marker. A, amplicon. B) Growing curves in glucose or galactose media. C) Oxygen consumption. E, 
endogenous respiration; L, leaking respiration; and U, uncoupled respiration. White, grey and black bars 
represent Owt, O8344 and O8357 cybrids, respectively. *, p < 0.05 (vs Owt). D) Respiratory complex IV 
(CIV) specific activity (s.a.) normalized by citrate synthase (CS) s.a. E) CIV quantity (q.) normalized by CS 
s.a. F) Western blot showing the amount of the mtDNA-encoded p.MT-CO1 subunit from CIV. The levels of 
the nDNA-encoded SDHA subunit from respiratory complex II (CII) have been used to normalize. 
































































2 + 1 m.8344A>G (2) 1-4
1 + 1 m.8344A>G (1) 5,6 
4 m.8344A>G (3) + MD (1) 7,8 
1 MD (1) 9,10
1 m.8344A>G (1) 11
1 + 8 m.8344A>G (1) 12 
1 SD (1) 13 
1 m.8363G>A (1) 14 
1 m.3243A>G (1) 15
1 m.8344A>G (1) 10,16
1 m.3264T>C (1) 17 NCP
1 + 17 m.8344A>G (1) 18
1 + 7 m.8344A>G (1) 19-21
1 + 2 m.8363G>A (1) 22
1 + ? MD (1) 23
1 m.8344A>G (1) 24
2 + 2 m.8344A>G (2) 25
1 SD (1) 26
1 m.8344A>G (1) 27
3 SD (3) 28
1 m.3271T>C (1) 29 only one small lipoma
2 m.8344A>G (2) 30
2 m.8344A>G (2) 31
1 + 2 m.8363G>A (1) 21,32
1 m.3243A>G (1) 33 Mutation % ≤ 0.102 
1 m.8344A>G (1) 21
1 m.8344A>G (1) 34
1 m.8344A>G (1) 35 
1 m.8344A>G (1) 36
1 m.4302A>G (1) 37 NCP
1 m.8344A>G (1) 30,38
1 + 6 m.8344A>G (1) 39
4 + 3 m.8344A>G (4) 40
1 + 1 m.8344A>G (1) 41
1 m.8344A>G + m.14484T>C (1) 42
1 m.8344A>G (1) 43
2 + 2 m.8344A>G (1) + m.8363G>A (1) 44
1 m.8344A>G (1) 45
1 + 9 m.8344A>G (1) 46
Supplemental Table. Multiple symmetric lipomatosis and mitochondrial DNA mutations. 
MD, multiple deletions. SD, single deletion. NCP, Non-confirmed pathogenicity. 
19 probands + 3 relatives are reported in 47 but they do not clarify whether some of them 
have been previously described.
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